Composition of the data monitoring committee, its role and reporting structure {21a}
ADVERSE EVENTS, ADVERSE EVENT
There is no data monitoring committee for this study, given the minimal safety concerns with the use of oral gabapentin. However, any serious adverse events will be evaluated by the trial steering committee and subsequently reported promptly to the Institute Ethics Sub Committee for Monitoring of Adverse Events in Clinical Trials at the site.